From MarketBeat:



Roivant Sciences Ltd. (NASDAQ:ROIV) experienced notable options trading activity, with an increase of 169% in call options volume. In other news, major shareholders sold substantial numbers of company shares. Furthermore, several large investors have recently increased their stakes in ROIV, and analysts have issued a “Moderate Buy” rating for the company. Roivant Sciences stock traded at $11.44 on Tuesday.

This commercial-stage biopharmaceutical company uses Vants, a model that focuses on partnerships with biopharmaceutical businesses, discovery-stage companies, and health technology startups. Lastly, while Roivant Sciences has a “Moderate Buy” rating among analysts, top-rated analysts have recommended five other stocks as better buys. Some of these stocks are excellent options for beginning investors hoping to build a long-term portfolio.

The article was generated using narrative science technology and financial data from MarketBeat and was reviewed by MarketBeat’s editorial team before publication. For the full details, check MarketBeat’s latest stock report on ROIV.



Read more: Roivant Sciences Sees Unusually Large Options Volume (NASDAQ:ROIV)